Experimental agent briefly eases depression rapidly in test
Works in brain like ketamine, with fewer side effects – NIH trial
A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.
This page was last updated on Friday, January 21, 2022